References
- Smit AJ, Lutgers HL. The clinical relevance of AGE and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004; 11: 2767–2784
- Nienhuis HL, de Leeuw K, Bijzet J, et al. Skin autofluorescence is increased in SLE but is not reflected by elevated plasma levels of AGE. Rheumatology (Oxford) 2008; 47: 1554–1558
- Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. RAGE is induced by AGE themselves and TNF-α through NF-κB, and by 17beta-estradiol through Sp-1 in HUVEC. J Biol Chem 2000; 275: 25781–25790
- Zhong Y, Li SH, Liu SM, et al. CRP upregulates RAGE expression in human endothelial cells. Hypertension 2006; 48: 504–511
- Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apoE-null mice. Circulation 2002; 106: 2827–2835
- Basta G. RAGE and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9–21
- Basta G, Lazzerini G, Massaro M, et al. AGE activate endothelium through RAGE: A mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816–822
- Chavakis T, Bierhaus A, Al Fakhri N, et al. RAGE is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507–1515
- Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE. Binding of RAGE ligands is not sufficient to induce inflammatory signals: Lack of activity of endotoxin-free albumin-derived AGE. Diabetologia 2004; 47: 844–852
- Ballinger ML, Thomas MC, Nigro J, Ivey ME, Dilley RJ, Little PJ. Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells. Kidney Int 2005; 68: 2756–2765
- Buetler TM, Leclerc E, Baumeyer A, et al. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 2008; 52: 370–378
- Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of RAGE expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370: 1097–1109
- Raucci A, Cugosi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolitic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM 10). FASEB J 2008; 22(10)3716–3727
- Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of sRAGE and circulating AGE in T2DM. Diabetologia 2006; 49: 2756–2762
- Bopp C, Hofer S, Weitz J, et al. sRAGE is elevated in septic patients and associated with patients ouTCome. J Surg Res 2008; 147: 79–83
- Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of sRAGE are associated with inflammatory markers in patients with T2DM. Mol Med 2007; 13: 185–189
- Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. sRAGE triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006; 54: 3898–3907
- Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D'Angelo A. High levels of sRAGE may be a marker of extreme longevity in humans. J Am Geriatr Soc 2006; 54: 1149–1150
- Gross S, van Ree RM, Oterdoom LH, et al. Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation 2007; 84: 659–663
- Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of sRAGE and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032–1037
- Renard C, Chappey O, Wautier MP, et al. The human and rat recombinant RAGE have a high degree of homology but different pharmacokinetic properties in rats. J Pharmacol Exp Ther 1999; 290: 1458–1466